NSF awards Novonesis funding to advance cell-free biomanufacturing of HMO

DENMARK – The U.S. National Science Foundation (NSF) has awarded Novonesis funding through its Use-Inspired Acceleration of Protein Design (NSF USPRD) initiative for enabling cell-free synthesis of longer human milk oligosaccharides (HMOs). 

The effort aims to develop cost-effective methods for producing complex nutrients found in human breast milk—nutrients that are vital to infant health and development yet remain scarce in today’s infant formulas.

USPRD, managed by NSF TIP, brings together industry–academic teams via an Ideas Lab—a one-week brainstorming session with invited experts from industry, academia, and other sectors—to translate AI-enabled protein design into practical, market-ready solutions.

The USPRD initiative is designed to secure U.S. leadership in biotechnology by accelerating innovation to bring sustainable bio-based products to market in a highly competitive global landscape.

Tue Micheelsen, President of Novonesis North America & Head of Global Consumer Health, said, “These NSF awards highlight Novonesis’ leadership in developing innovative biosolutions that address human health and sustainability challenges.”

“I am especially proud of the impact our teams are having across the country. At Novonesis, we believe in using the power of biology to solve real-life challenges. This funding from NSF underscores both the promise of our science and the results our people can deliver for people and planet.”

Expanding Access to Complex Human Milk Oligosaccharides

HMOs are complex sugars that play a vital role in early-life immunity, brain development, and long-term health.

While infant formulas contain only a fraction of the simplest HMOs, the Novonesis-led project aims to enable large-scale, affordable synthesis of longer, more complex HMOs through advanced enzyme engineering and computational design.

The project brings together experts from Novonesis, Stanford University, and UC Davis to design specialized enzymes that can create longer, more complex human milk sugars (HMOs), use advanced artificial intelligence tools to speed up the process of predicting and improving enzyme performance,

They will also test enzymes in cell-free systems—platforms that work outside of living cells—to quickly screen as well as refine new ideas and evaluate real-world potential by ensuring the methods can be scaled up and remain cost-effective in industrial settings.

This initiative not only addresses critical gaps in infant nutrition but also contributes broadly to the protein design community by developing reusable models, new design algorithms, and openly shared datasets.  

These innovations will not only accelerate HMO research but also pave the way for broader applications in synthetic biology, enabling a new generation of AI-driven breakthroughs in enzyme and protein design, and pioneering new pathways in biomanufacturing.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE